MPR

Novel siRNA Therapy for Hereditary Angioedema Receives Fast Track Status

The FDA awards Fast Track designation to BW-20805 for hereditary angioedema, a therapy designed to reduce attacks through PKK suppression.

BioCryst (BCRX) soars 13% on acquisition buzz

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is one of the 10 Stocks Worth Watching Right Now. BioCryst snapped a three-day ...

Argo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

Pharvaris N.V.: Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAP ...

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of ...
Medical Dialogues

Switch to Garadacimab Shows Strong Safety, Zero Hereditary Angioedema Attacks in Interim Study

USA: Switching to garadacimab may provide a safe and effective option for preventing hereditary angioedema (HAE) attacks, according to interim findings from an ongoing Phase 4 clinical study. Patients ...
The Manila Times

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and ...
Healio

Navenibart safe, lowers hereditary angioedema attack rate up to 24 months

Please provide your email address to receive an email when new articles are posted on . Subcutaneous navenibart was given as either 600 mg then 300 mg every 3 months or 600 mg every 6 months. Both ...

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution ...

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) ...